カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のベバシズマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Bevacizumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23SM7788）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23SM7788
■ 発行日：2023年9月
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：72
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥508,080見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥762,120見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,016,160見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のベバシズマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界のベバシズマブモノクローナル抗体バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のベバシズマブモノクローナル抗体バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- ベバシズマブモノクローナル抗体バイオシミラーの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

ベバシズマブモノクローナル抗体バイオシミラー市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・400mg、100mg

用途別セグメント
・がん、加齢黄斑変性症、その他

主要な市場プレーヤー
・Celltrion、Amneal、Pfizer、Amgen

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ベバシズマブモノクローナル抗体バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なベバシズマブモノクローナル抗体バイオシミラーメーカーの企業概要、2019年～2022年までのベバシズマブモノクローナル抗体バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なベバシズマブモノクローナル抗体バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別ベバシズマブモノクローナル抗体バイオシミラーの販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのベバシズマブモノクローナル抗体バイオシミラーのタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのベバシズマブモノクローナル抗体バイオシミラー市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびベバシズマブモノクローナル抗体バイオシミラーの産業チェーンを掲載しています。
・第14、15章では、ベバシズマブモノクローナル抗体バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– ベバシズマブモノクローナル抗体バイオシミラーの概要
– タイプ別分析（2018年vs2022年vs2029年）：400mg、100mg
– 用途別分析（2018年vs2022年vs2029年）：がん、加齢黄斑変性症、その他
– 世界のベバシズマブモノクローナル抗体バイオシミラー市場規模・予測
– 世界のベバシズマブモノクローナル抗体バイオシミラー生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Celltrion、Amneal、Pfizer、Amgen
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：400mg、100mg
・用途別分析2018年-2029年：がん、加齢黄斑変性症、その他
・ベバシズマブモノクローナル抗体バイオシミラーの北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ベバシズマブモノクローナル抗体バイオシミラーのヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ベバシズマブモノクローナル抗体バイオシミラーのアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ベバシズマブモノクローナル抗体バイオシミラーの南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・ベバシズマブモノクローナル抗体バイオシミラーの中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Bevacizumab Monoclonal Antibody Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 400mg
1.3.3 100mg
1.4 Market Analysis by Application
1.4.1 Overview: Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Wet Age-related Macular Degeneration
1.4.4 Other
1.5 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size & Forecast
1.5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.1.4 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Celltrion Recent Developments/Updates
2.2 Amneal
2.2.1 Amneal Details
2.2.2 Amneal Major Business
2.2.3 Amneal Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.2.4 Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amneal Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.3.4 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.4.4 Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amgen Recent Developments/Updates
3 Competitive Environment: Bevacizumab Monoclonal Antibody Biosimilar by Manufacturer
3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Bevacizumab Monoclonal Antibody Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.5 Bevacizumab Monoclonal Antibody Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Bevacizumab Monoclonal Antibody Biosimilar Market: Region Footprint
3.5.2 Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
3.5.3 Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region
4.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2029)
4.2 North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.5 South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
7.3.1 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
8.3.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region
9.3.1 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
10.3.1 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
11.3.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
12.2 Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
12.3 Bevacizumab Monoclonal Antibody Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Bevacizumab Monoclonal Antibody Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bevacizumab Monoclonal Antibody Biosimilar
13.3 Bevacizumab Monoclonal Antibody Biosimilar Production Process
13.4 Bevacizumab Monoclonal Antibody Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bevacizumab Monoclonal Antibody Biosimilar Typical Distributors
14.3 Bevacizumab Monoclonal Antibody Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product and Services
Table 6. Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Celltrion Recent Developments/Updates
Table 8. Amneal Basic Information, Manufacturing Base and Competitors
Table 9. Amneal Major Business
Table 10. Amneal Bevacizumab Monoclonal Antibody Biosimilar Product and Services
Table 11. Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amneal Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product and Services
Table 16. Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Amgen Basic Information, Manufacturing Base and Competitors
Table 19. Amgen Major Business
Table 20. Amgen Bevacizumab Monoclonal Antibody Biosimilar Product and Services
Table 21. Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Amgen Recent Developments/Updates
Table 23. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 24. Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 25. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 26. Market Position of Manufacturers in Bevacizumab Monoclonal Antibody Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 27. Head Office and Bevacizumab Monoclonal Antibody Biosimilar Production Site of Key Manufacturer
Table 28. Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
Table 29. Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
Table 30. Bevacizumab Monoclonal Antibody Biosimilar New Market Entrants and Barriers to Market Entry
Table 31. Bevacizumab Monoclonal Antibody Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 32. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 33. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 34. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 35. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 36. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 37. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 38. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 39. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 40. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 41. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 42. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 43. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 44. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 45. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 46. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 47. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 48. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 49. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 50. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 52. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 53. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 54. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 55. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 56. North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 57. North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 58. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 61. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 62. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 63. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 64. Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 65. Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 66. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 67. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 68. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 70. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 71. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 72. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 73. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 74. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 75. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 76. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 77. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 78. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 79. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 80. South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 81. South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 82. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 83. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 84. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 87. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 88. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 89. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 90. Bevacizumab Monoclonal Antibody Biosimilar Raw Material
Table 91. Key Manufacturers of Bevacizumab Monoclonal Antibody Biosimilar Raw Materials
Table 92. Bevacizumab Monoclonal Antibody Biosimilar Typical Distributors
Table 93. Bevacizumab Monoclonal Antibody Biosimilar Typical Customers
List of Figures
Figure 1. Bevacizumab Monoclonal Antibody Biosimilar Picture
Figure 2. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. 400mg Examples
Figure 5. 100mg Examples
Figure 6. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Cancer Examples
Figure 9. Wet Age-related Macular Degeneration Examples
Figure 10. Other Examples
Figure 11. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Bevacizumab Monoclonal Antibody Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 53. China Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
Figure 74. Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
Figure 75. Bevacizumab Monoclonal Antibody Biosimilar Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Bevacizumab Monoclonal Antibody Biosimilar in 2022
Figure 78. Manufacturing Process Analysis of Bevacizumab Monoclonal Antibody Biosimilar
Figure 79. Bevacizumab Monoclonal Antibody Biosimilar Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のアダリムマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のレミケード（インフリキシマブ）モノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析
  • 世界のリツキサン（リツキシマブ）モノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析
  • 世界のチロゲン&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のアバスチンバイオシミラー市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23SM7788 )"世界のベバシズマブモノクローナル抗体バイオシミラー市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Bevacizumab Monoclonal Antibody Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。